Ask AI
ProCE Banner Activity

1801 Part 3B: Preliminary Results From a Phase II Study of Elraglusib + Gemcitabine/nab-Paclitaxel (GnP) vs GnP in Previously Untreated mPDAC

Conference Coverage
Slideset

Preliminary results from the open-label, randomized phase II 1801 Part 3B trial suggest that addition of the novel GSK-3β inhibitor elraglusib to gemcitabine/nab-paclitaxel is associated with a significant improvement in overall survival in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.

Released: June 11, 2025

Expiration: December 10, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Daiichi Sankyo, Inc. and Genentech, a member of the Roche Group.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group